Rezdiffra Uptake Held Up By Payers, But Not Biopsy Requirements

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Several factors are delaying fulfillment of MASH prescriptions, but payers are not holding out for biopsy disease confirmation. KOLs cited by Leerink also call tirzepatide the clear standout in obesity, though access issues are still an issue.

Frederic Muller/Shutterstock.com
KOLs expect incretins to hold large market share in obesity, MASH

Initial prescriptions for Madrigal Pharmaceuticals, Inc.’s Rezdiffra (resmetirom) are running into payer-related delays, but not because payers want biopsy-based disease confirmation, according to key opinion leaders discussing the metabolic dysfunction-associated steatohepatitis (MASH) and obesity treatment landscapes at a recent Leerink Partners event. Meanwhile, a note issued by Leerink on 14 July cited KOLs saying Eli Lilly and Company’s Zepbound (tirzepatide) offers the best overall clinical profile in obesity therapy.

During an inflammation and immunology therapeutics forum convened by Leerink on 9 July, the firm’s analysts interviewed a pair of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains